Generated by AI
Korsana Biosciences, Inc. Common Stock represents the equity of Korsana Biosciences, a biotechnology company focused on developing novel therapies for neurodegenerative diseases. The company’s current work centers on brain-penetrant therapeutics built around its proprietary THETA blood-brain-barrier shuttle platform, which is designed to improve delivery of large molecules into the central nervous system. Its lead program, KRSA-028, is an investigational antibody targeting amyloid beta for Alzheimer’s disease, alongside additional pipeline assets aimed at other neurodegenerative conditions. Korsana’s business is centered on discovering, advancing, and eventually commercializing precision-engineered medicines for serious brain disorders, making it a specialized participant in the biopharmaceutical market focused on central nervous system innovation. The company is based in Waltham, Massachusetts.
Website245 First Street, Riverview II
Cambridge, MA, 02142
United States
Summary of Sep 9's posts. Generated by AI.
Summary of Apr 9's posts. Generated by AI.
Summary of Apr 9's posts. Generated by AI.
Investors talking about CYCN also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.